Prospera Financial Services Inc Has $983,000 Stock Holdings in Danaher Corporation $DHR

Prospera Financial Services Inc raised its holdings in Danaher Corporation (NYSE:DHR) by 16.0% during the second quarter, Holdings Channel.com reports. The fund owned 4,972 shares of the conglomerate’s stock after purchasing an additional 684 shares during the period. Prospera Financial Services Inc’s holdings in Danaher were worth $983,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Danaher by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate’s stock worth $12,296,123,000 after purchasing an additional 230,966 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Danaher by 3.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock valued at $4,016,404,000 after purchasing an additional 612,154 shares during the last quarter. Invesco Ltd. lifted its stake in Danaher by 44.5% in the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after buying an additional 1,450,703 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Danaher by 4.0% during the first quarter. Charles Schwab Investment Management Inc. now owns 4,230,087 shares of the conglomerate’s stock worth $867,168,000 after buying an additional 163,332 shares during the last quarter. Finally, Nuveen LLC acquired a new position in shares of Danaher during the 1st quarter worth about $833,941,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Trading Up 1.8%

Shares of NYSE:DHR opened at $219.60 on Thursday. The firm has a market cap of $155.11 billion, a price-to-earnings ratio of 45.28, a PEG ratio of 3.28 and a beta of 0.81. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $258.23. The company’s fifty day simple moving average is $204.76 and its 200 day simple moving average is $200.77. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The firm had revenue of $6.05 billion during the quarter, compared to analyst estimates of $6 billion. During the same period in the prior year, the business earned $1.71 EPS. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, research analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Friday, September 26th were given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Friday, September 26th. Danaher’s dividend payout ratio (DPR) is currently 26.39%.

Insider Activity at Danaher

In other Danaher news, Director Teri List sold 2,778 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the sale, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Georgeann Couchara sold 5,174 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the transaction, the senior vice president directly owned 2,625 shares of the company’s stock, valued at $552,352.50. This represents a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 11.20% of the company’s stock.

Analyst Upgrades and Downgrades

DHR has been the topic of several recent analyst reports. UBS Group reduced their price objective on shares of Danaher from $240.00 to $225.00 and set a “buy” rating on the stock in a research note on Wednesday, July 23rd. JPMorgan Chase & Co. increased their target price on shares of Danaher from $260.00 to $270.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Wells Fargo & Company reissued a “positive” rating on shares of Danaher in a report on Thursday, October 23rd. Royal Bank Of Canada set a $241.00 price objective on shares of Danaher in a research report on Tuesday, September 2nd. Finally, Evercore ISI lifted their target price on Danaher from $226.00 to $245.00 and gave the stock an “outperform” rating in a report on Tuesday, October 7th. Eighteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $243.39.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.